Brief: Sorrento Reports Positive Trial Results Utilizing Sofusa Lymphatic Delivery Of Etanercept
15/09/2022 14:50
Sept 15 (Reuters) - Sorrento Therapeutics Inc SRNE.O :
* SORRENTO REPORTS POSITIVE TRIAL RESULTS UTILIZING SOFUSA
LYMPHATIC DELIVERY OF ETANERCEPT, ACHIEVING SIGNIFICANT
IMPROVEMENTS IN RHEUMATOID ARTHRITIS DISEASE MEASURES AT 50% OF
STANDARD DOSE FOR PATIENTS (7 OF 7) WITH AN INADEQUATE RESPONSE
TO SUBCUTANEOUS INJECTIONS
Source text for Eikon: ID:nGNX828Zt7
Further company coverage: SRNE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20